Cynata Therapeutics Limited (CYP.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEST
| Previous close | 0.3750 |
| Open | 0.3750 |
| Bid | 0.3650 x 1582700 |
| Ask | 0.3800 x 3535900 |
| Day's range | 0.3650 - 0.3800 |
| 52-week range | 0.3450 - 0.6400 |
| Volume | |
| Avg. volume | 86,786 |
| Market cap | 54.445M |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0280 |
| Earnings date | 29 Aug 2022 - 02 Sept 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- PR Newswire
US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD
Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the United States (US) Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Cynata's Phase 2 clinical trial of CYP-001[1], Cynata's lead product, in patients with acute graft versus host disease (aGvHD).
- Simply Wall St.
We Think Cynata Therapeutics (ASX:CYP) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
© 2022 Yahoo. All rights reserved.
